1. Home
  2. FRD vs GANX Comparison

FRD vs GANX Comparison

Compare FRD & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Friedman Industries Inc.

FRD

Friedman Industries Inc.

HOLD

Current Price

$18.33

Market Cap

134.3M

Sector

Industrials

ML Signal

HOLD

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

HOLD

Current Price

$2.72

Market Cap

159.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FRD
GANX
Founded
1965
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Steel/Iron Ore
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
134.3M
159.2M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
FRD
GANX
Price
$18.33
$2.72
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$8.00
AVG Volume (30 Days)
21.8K
499.4K
Earning Date
05-18-2026
01-01-0001
Dividend Yield
0.89%
N/A
EPS Growth
N/A
47.95
EPS
1.46
N/A
Revenue
$121,157,278.00
$55,180.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$12.64
N/A
Revenue Growth
55.82
N/A
52 Week Low
$12.24
$1.41
52 Week High
$24.37
$4.34

Technical Indicators

Market Signals
Indicator
FRD
GANX
Relative Strength Index (RSI) 41.70 54.94
Support Level $18.54 $1.56
Resistance Level $20.60 $2.40
Average True Range (ATR) 1.19 0.12
MACD -0.19 0.08
Stochastic Oscillator 12.89 92.59

Price Performance

Historical Comparison
FRD
GANX

About FRD Friedman Industries Inc.

Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Share on Social Networks: